Acarbose Use in Compensated Cirrhosis: Indications, Dosing, Safety, and Clinical Considerations

Patient Selection & Contraindications

Absolute contraindication: Acarbose must not be used in patients with decompensated cirrhosis (Child‑Pugh class C) presenting with ascites, hepatic encephalopathy, variceal bleeding, or jaundice. 1
Baseline eligibility assessment: Confirmation of compensated liver disease (Child‑Pugh class A or early B) is required before initiating therapy. 2

Gradual titration reduces gastrointestinal intolerance: Starting at 50 mg three times daily and increasing to 100 mg three times daily after two weeks minimizes abdominal distension and flatulence, common adverse effects of α‑glucosidase inhibitors. 3

Child‑Pugh classification as a monitoring anchor: Ongoing assessment of liver functional class guides dose adjustments and safety surveillance. 2

Hypoglycemia risk: Unlike sulfonylureas, acarbose does not cause hypoglycemia when used as monotherapy. 3
Initiation setting: Acarbose can be started in the outpatient setting for compensated cirrhosis, whereas insulin typically requires hospital initiation. 1
GLP‑1 receptor agonist limitation: These agents are recommended only for patients with Child‑Pugh class A cirrhosis. 4
SGLT2 inhibitor use: SGLT2 inhibitors are permissible in Child‑Pugh class A and B patients but carry a risk of volume depletion. 4

Avoid use in decompensated cirrhosis: Prescribing acarbose to Child‑Pugh class C patients is unsafe; insulin remains the appropriate therapy. 1
Patient counseling on hypoglycemia management: If rare hypoglycemia occurs, patients should be instructed to treat it with rapid‑acting glucose or honey rather than sucrose or starch. 3